KPV: What It Is, Where to Get It Prescribed, and What It Costs

KPV is a tripeptide — three amino acids, lysine-proline-valine, which is where the name comes from. It is the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a thirteen-amino-acid hormone the body makes from the precursor pro-opiomelanocortin. In the literature it is often written as alpha-MSH(11-13), positions eleven to thirteen of the parent molecule.

That parentage matters. Alpha-MSH is best known for driving pigmentation, but it has a second, well-documented role as an anti-inflammatory signal the body uses to keep immune responses in check. KPV is an attempt to isolate that second role from the first.

Researchers working on alpha-MSH noticed that its anti-inflammatory effects tracked with the C-terminal end of the molecule. A 2008 review in Endocrine Reviews sets this out: the three-amino-acid tail retained much of the anti-inflammatory and protective activity of the parent hormone in cell and animal models, while pigmentation depends on a different part of the sequence. Isolating KPV keeps the signalling of interest and leaves the tanning behind.

It is not a hormone in its own right and it is not a steroid. It does not suppress any hormone production of your own and carries no anabolic activity.

It is not a corticosteroid and it is not a substitute for one; a patient on prescribed treatment for a diagnosed inflammatory disease should not be swapping that treatment for a peptide. It is not a painkiller; nothing in the literature describes an analgesic mechanism. And it is not a tanning peptide — that is Melanotan II, a different molecule.

The most specific mechanism described is how KPV enters cells. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal epithelial cells by PepT1, the transporter the gut lining uses to absorb small peptides from food, and that its effect on inflammatory signalling depended on the transporter being present. This is unusual for a peptide — most act at a receptor on the cell surface — and it is the basis for the claim that KPV works from inside the cell.

Once inside, KPV is described as interfering with two of the main intracellular pathways that turn an inflammatory trigger into an inflammatory response: NF-kB and MAPK. NF-kB is the switch that, when activated, moves into the nucleus and starts transcription of pro-inflammatory genes. The Gastroenterology work and a 2008 paper in Inflammatory Bowel Diseases both describe reduced NF-kB activation in cells and in inflamed mouse colon.

The downstream result, in the cell and mouse work, is less production of the cytokines that drive and sustain inflammation — TNF-alpha, IL-6, IL-1beta, IL-8 and others depending on the model. This is a "less fuel on the fire" description rather than a "puts the fire out" one.

Alpha-MSH works largely through melanocortin receptors, and the melanocortin-1 receptor is the one that drives pigmentation. A 2012 paper in the International Journal of Physiology, Pathophysiology and Pharmacology examined KPV in a human bronchial epithelial cell line and described it inhibiting cytokine-driven NF-kB activation through a route that did not depend on that receptor. That is why KPV is described as anti-inflammatory without being a pigmenting agent.

An older line of work, reported in the Journal of Leukocyte Biology in 2000, described alpha-MSH and the KPV fragment reducing colony formation of Staphylococcus aureus and germination of Candida albicans in the laboratory. This is a test-tube observation, not a treatment claim, but it is part of why "wound healing" was one of the two uses the FDA's advisory committee considered in 2026.

This is the deepest and most consistent body of work. The 2008 Inflammatory Bowel Diseases paper reported reduced weight loss and reduced histological inflammation in mice with chemically induced colitis and in IL-10-deficient mice, a model of chronic colitis. The 2008 Gastroenterology paper reported that KPV given orally in drinking water reduced the severity of two different chemically induced colitis models, and tied the effect to the PepT1 transporter.

A 2017 paper in Molecular Therapy packaged KPV in hyaluronic-acid-coated nanoparticles designed to reach inflamed colon, and reported reduced colitis in mice at a far lower total dose than free peptide in drinking water. That is a formulation study — no compounding pharmacy supplies that delivery system — but it is the most recent substantial preclinical work on the compound.

The Endocrine Reviews 2008 summary covers alpha-MSH and its C-terminal fragment in models of skin inflammation, including contact hypersensitivity in mice, and in cultured keratinocytes. The direction of effect is the same as in the gut: less cytokine output and less NF-kB activation. The KPV-specific skin literature is thinner than the gut literature, and much of it is on the parent hormone rather than the tripeptide alone.

The 2012 human bronchial epithelial cell work above is the main airway study. A 2013 paper in PLoS One reported that a single dose of alpha-MSH(11-13) after experimental traumatic brain injury in mice reduced lesion volume and markers of inflammation and cell death. These are single studies in single models; they do not establish KPV as a treatment in those tissues.

This is the part worth reading before starting. There are no randomised controlled trials of KPV in humans, and no published human trials of KPV as a single agent of any design. The nearest thing to human data is work on human cell lines — intestinal epithelial, T-cell and bronchial epithelial — which shows the mechanism operates in human cells but says nothing about what happens when a person injects it.

That is a narrower evidence base than BPC-157, which at least has early-phase human work for inflammatory bowel indications. For KPV the honest framing is "well characterised in cells and mice, used clinically on the strength of that, not studied in people."

• It does not establish an effect in any human condition, an effect size or a timeline. A mouse with chemically induced colitis is not a person with an inflammatory condition, and the human trial has not been run.
• It does not establish that injecting it does what putting it in a mouse's drinking water does. Most of the gut work used the oral route deliberately, because of the PepT1 transporter; the subcutaneous route prescribers use has not been compared.
• It does not establish long-term safety over months or years of use.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything.

Prescribers generally describe this as a settling-in window. Where people report anything, it is usually background inflammation being quieter rather than a specific change. Many people notice nothing at all in the first two weeks, which is normal and not a sign the course is failing.

This is the window most courses are built around and the reason a vial is sized at about four weeks of Monday-to-Friday dosing. If a change in the underlying complaint is going to be noticed, prescribers describe it as tending to show here. Gut-related complaints are the ones most often described as responding, which fits where the animal work is strongest.

Whether a second vial is prescribed depends on what happened during the first. A physician who sees a clear change will often continue; one who sees nothing after a full vial will usually reconsider rather than repeat. There is no research on prolonged use.

There is no withdrawal and no rebound described in the literature; KPV does not shut down a system that then has to restart. Whether any benefit persists after stopping depends on what was driving the inflammation to begin with, which is the same question that applies to any anti-inflammatory approach.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. The mechanisms described for KPV are systemic, so there is no particular reason to inject near a sore area.

The directions are Monday through Friday, not seven days a week. Five doses a week for four weeks is 20 doses, which is exactly what a vial holds at 0.25 mL per dose, and why refills run on a 28-day cycle. The weekend gap is part of the schedule as reviewed, not something to fill in on your own. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Once punctured, keep the vial in the refrigerator between doses. Beyond-use dating runs from first puncture and is printed on the label.

Different jobs, often confused because both come up for gut complaints. BPC-157 is described around blood vessel growth, cell migration and protection of the gut lining — a repair story. KPV is described around damping the signalling that produces inflammatory cytokines — an immune-signalling story. BPC-157 has early-phase human work; KPV has none. They are frequently prescribed together, and the FORTIFY blend puts them in one vial.

Thymosin Alpha-1 is a much larger peptide described around immune regulation — T-cell activity and immune surveillance — with a substantial human literature in countries where it is an approved product. KPV is small, acts inside the cell, and has no human literature. If the question is "my immune system needs support," Thymosin Alpha-1 is the more direct conversation; if it is "my body is producing more inflammatory signalling than it should," KPV is. A physician may suggest either, or both.

On its own, KPV is one variable, which makes it easier to judge whether it is doing anything. In the FORTIFY or ELEVATE blends it is one of four actives, for people who already want the combination in one injection. Neither is clinically better; the blend is a convenience, not a stronger version.